Loading...
Loading...
AVI BioPharma, Inc.
AVII, a developer of RNA-based therapeutics, today
announced that it has received approval from the Food and Drug
Administration (FDA) to proceed with a single oligomer, AVI-7288, in
studies in both humans and non-human primates to support the safety
and efficacy of post-exposure prophylaxis against Marburg virus
infection. AVI-7288 is one of two components that make up AVI-6003.
Studies conducted to date have shown that efficacy in non-human
primates can be attributed to this single component, while the second
component, AVI-7287, does not appear to contribute to efficacy.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in